Overview
- In a 2025 matched real‑world analysis presented at the ASMBS meeting, New York University researchers found bariatric surgery patients lost about 25.7% of total body weight over two years versus roughly 5.3% for patients prescribed GLP‑1 medications.
- Insurance‑claims research reported in JAMA Surgery shows GLP‑1 prescriptions surged by more than 140% between 2022 and 2024 while bariatric surgery claims fell by about 34%, widening the gap between drug and surgical treatment rates.
- Real‑world effectiveness of GLP‑1s is limited by wide individual variation in response and high drop‑off, with researchers reporting that as many as about 70% of patients stop treatment within a year due to side effects, cost or other barriers.
- New observational analyses presented at ECO 2026 and ASCO 2026 linked larger GLP‑1‑associated BMI reductions to substantially lower risks of conditions such as sleep apnea, chronic kidney disease and some cancer progression, but the studies cannot prove causation.
- Beyond health outcomes, rising GLP‑1 use is changing everyday life by cutting grocery and restaurant spending, shifting retail assortments and prompting early neuroscience signals of altered brain connectivity, all of which deepen debates over equity, long‑term monitoring and treatment choice.